The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

Get Instant Summarized Text (Gist) The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and a blood eosinophil count ≥150 ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL. The FDA has approved GSK’s Nucala ...